[ TRANSACTION RECORD ]

JPMorgan Chase & Co. Investment in Karuna Therapeutics Inc. — 2023

VERIFIED VECTOR ID: 002135 · tx-231
M SOURCE NODE — FUNDER
JPMorgan Chase & Co.
Finance United States
$14,000,000,000
EQUITY
22/12/2023
Q DESTINATION NODE — RECIPIENT
Karuna Therapeutics Inc.
Company United States
Amount (USD)
$14.0B
Flow Type
EQUITY
Transaction Date
22/12/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity JPMorgan Chase & Co.
AUM 3900000
HQ Location United States
Sector Finance
Recipient Profile [ Q ]
Entity Karuna Therapeutics Inc.
Entity Type Company
Jurisdiction United States
Intelligence Note

Bristol Myers Squibb entered into an agreement to acquire Karuna Therapeutics for 14 billion dollars to expand its neuroscience portfolio with a novel treatment for schizophrenia. This transaction centers on the clinical-stage drug KarXT, which targets muscarinic receptors. The deal underscores the institutional focus on transformative neurological and psychiatric healthcare.

Σ
Primary Forensic Source https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Acquire-Karuna-Therapeutics/
✓ SOURCE LINKED